India’s In-Vitro Diagnostics Market Double Digit Annual Growth Drove Stronger

Adoption of Automation With Over 1,800 Automated Systems Detected in 2007

Clearstate’s IVD Gateway Database in India provides insights on instrument installation and test
consumption trends by tracking market changes and usage patterns quarterly.

March 19, 2008, Singapore – Following the successful launch of its South East Asia (SEA) usage
database for In-vitro Diagnostics (IVD) in 2006, Clearstate has expanded its IVD Gateway
Database coverage to one of the largest and most challenging market in the region, India.

India’s large geography and non-homogeneous usage environment demand a large sampling of
hospital and stand-alone laboratories to ensure a robust and well-represented analysis of the IVD
market. The Gateway database screened over 5,000 labs and surveyed in detail over 800 of the
highest test volume facilities in India. Clearstate also took an additional measure to increase the
thoroughness of the survey input and sizing estimates through validation with major distributors and
suppliers.

Similar to the SEA database, the India database details unit installation of diagnostics analyzers,
the volume consumption of reagents and tests assays, and the penetration of key IVD brands by
city, model and user segment.

However, according to Ms. Ivy Teh, Clearstate’s Managing Director, “We have further improved our
database offering by providing value-added interpretations of market insights and share analysis.
Instead of just presenting data, we now provide analysis on test breakdown run on automated vs.
semi-automated systems, we have average installation age of over 10 leading brands and models
and where they are located to help clients determine where and when replacements are coming
up.”

Ms. Teh added that the improved database showed more technology adoptions and higher end
automated equipment purchases in large lab facilities especially in the South and West regions of
India. For instance, automated systems in Clinical Chemistry have grown to close to 1,800 units
across India, that represents only 12 – 15% of total analyzers installed but nearly 50% of the total
revenue, valued at approximately USD 35 - 40 million in 2007. Trends observed in the database
also revealed that local players are gaining stronger market presence, with Transasia extending its
market leadership over international players specifically in Clinical Chemistry and Hematology.

Other interesting insights extracted from India’s IVD Gateway include:

Determine brand share and placements: Transasia’s Erba Chem Series and Bayer’s
small RA Systems are the most placed Clinical Chemistry (CC) analyzers in all types of
facilities. These analyzers act as back-up instruments in larger lab facilities. Bayer is
pushing more of it Advia Systems that has seen a jump in installations in recent years while
phasing out the old RA systems.

Assess opportunity by geography: South and West India have the highest demand for
IVD tests relative to other regions in the country, representing over 60% of total IVD tests.
The majority of tests are still centered around key urban cities, primarily Mumbai, Delhi,
Chennai, Bangalore and Kolkata.

About Clearstate’s Gateway Database

The Gateway database is a unique healthcare service by Clearstate, a niche healthcare
consultancy, developed to provide accurate, reliable and comprehensive information on medical
device usage and demand across Asia Pacific. We deliver actual and up-to-date placement, usage
and consumption data for devices, equipment and consumables found in healthcare and
commercial settings.

For more information, visit our web site at www.clearstate.com or call +65 6303 5030

1
www.clearstate.com